Jeffrey Bacha

Jeffrey A. Bacha was the founder of Kintara Therapeutics, Inc., founded in 2009, where the title held was Director in 2018.
Mr. Bacha is the founder of Del Mar Pharmaceuticals (BC) Ltd., founded in 2010, holding the titles of President, Chief Executive Officer & Director since 2012.
Mr. Bacha is the founder of Edison Oncology Holding Corp., founded in 2018, serving as Chief Executive Officer & Director starting in 2025.
Current jobs include CEO, Chief Financial Officer & Director at NewGen Therapeutics, Inc.; Non-Executive Chairman at Rakovina Therapeutics, Inc. since 2026; Independent Director at AD4 Capital Corp.
since 2021; Director at Leukemia & Lymphoma Society Greater San Francisco Bay Area since 2018; and Member-Research Roundtable at National Brain Tumor Society, Inc. Former jobs include President & Chief Executive Officer at Inimex Pharmaceuticals, Inc. from 1999 to 2004; Chairman at Covenant House Vancouver; Independent Director at Sernova Biotherapeutics, Inc. from 2008 to 2022; Director at CalEthos, Inc. from 2008 to 2009; Founding Director at Urigen Holdings, Inc.; Director & Senior Manager at KPMG Health Ventures from 1995 to 1999; Chief Operating Officer & Executive Vice President at Clerac LLC from 2006 to 2009; Chief Financial Officer & VP-Corporate Development at XBiotech USA, Inc.; Chief Operating Officer & EVP-Corporate Affairs at Clera Inc. from 2005 to 2009; and Vice President-Corporate Development at EACOM Timber Corp.
in 2002.
Education includes an undergraduate degree from the University of California San Diego in 1991 and an MBA from Goizueta Business School-Emory in 1995.